AI is speeding up the search for new medicines. Can it make the discoveries themselves?
Few people are better placed to answer that than Dr. Elias Zerhouni. He ran the National Institutes of Health, then global R&D at Sanofi. He co-founded ModeX Therapeutics, which uses machine learning to design antibodies that don't exist in nature, and he is now vice chairman and president of its parent company, OPKO Health.
On the latest episode of KFF's The Business of Health, I sit down with Dr. Zerhouni to dig into what AI is actually doing in drug development, how the FDA stacks up against regulators abroad, and what a slowdown in AI could mean for the next generation of cures.
Listen to the latest episode of my podcast: kff.org/other-health/t…
Few people are better placed to answer that than Dr. Elias Zerhouni. He ran the National Institutes of Health, then global R&D at Sanofi. He co-founded ModeX Therapeutics, which uses machine learning to design antibodies that don't exist in nature, and he is now vice chairman and president of its parent company, OPKO Health.
On the latest episode of KFF's The Business of Health, I sit down with Dr. Zerhouni to dig into what AI is actually doing in drug development, how the FDA stacks up against regulators abroad, and what a slowdown in AI could mean for the next generation of cures.
Listen to the latest episode of my podcast: kff.org/other-health/t…
0:50